Dual pyroptotic biomarkers predict erythroid response in lower-risk non-del(5q) myelodysplastic syndromes treated with lenalidomide and recombinant erythropoietin

被引：4
|
作者：
Wang, Chen [1 ]
McGraw, Kathy L. [2 ]
McLemore, Amy F. [2 ]
Komrokji, Rami [2 ]
Basiorka, Ashley A. [2 ]
Al Ali, Najla [2 ]
Lancet, Jeffrey E. [2 ]
Padron, Eric [2 ]
Kosmider, Olivier [3 ]
Fontenay, Michaela [3 ]
Fenaux, Pierre [4 ]
List, Alan F. [2 ]
Sallman, David A. [2 ]
机构：
[1] Univ S Florida, Dept Internal Med, Morsani Coll Med, Tampa, FL USA
[2] H Lee Moffitt Canc Ctr & Res Inst, Dept Malignant Hematol, Tampa, FL USA
[3] Ctr Univ Paris, Serv Hematol Biol, Hop Cochin, Assistance Publ Hop Paris, Paris, France
[4] Hop St Louis, Grp Francophone Myelodysplasies, Paris, France
来源：
HAEMATOLOGICA | 2022年 / 107卷 / 03期
关键词：
MECHANISM;
D O I：
10.3324/haematol.2021.278855
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：737 / 739
页数：3
相关论文
共 50 条
  • [1] Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
    Madanat, Yazan F.
    Sekeres, Mikkael A.
    Mukherjee, Sudipto
    Hirsch, Cassandra M.
    Guan, Yihong
    Nagata, Yasunobu
    Adema, Vera
    Hasipek, Metis
    Gerds, Aaron T.
    Carraway, Hetty E.
    Advani, Anjali S.
    Przychodzen, Bartlomiej P.
    Santini, Valeria
    Maciejewski, Jaroslaw P.
    Jha, Babal K.
    Nazha, Aziz
    BLOOD, 2018, 132
  • [2] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Valeria Santini
    Pierre Fenaux
    Aristoteles Giagounidis
    Uwe Platzbecker
    Alan F. List
    Torsten Haferlach
    Jim Zhong
    Chengqing Wu
    Konstantinos Mavrommatis
    C. L. Beach
    Kyle J. MacBeth
    Antonio Almeida
    Leukemia, 2021, 35 : 897 - 900
  • [3] Impact of somatic mutations on response to lenalidomide in lower-risk non-del(5q) myelodysplastic syndromes patients
    Santini, Valeria
    Fenaux, Pierre
    Giagounidis, Aristoteles
    Platzbecker, Uwe
    List, Alan F.
    Haferlach, Torsten
    Zhong, Jim
    Wu, Chengqing
    Mavrommatis, Konstantinos
    Beach, C. L.
    MacBeth, Kyle J.
    Almeida, Antonio
    LEUKEMIA, 2021, 35 (03) : 897 - 900
  • [4] Lenalidomide for del(5q) and Non-del(5q) Myelodysplastic Syndromes
    Giagounidis, Aristoteles A. N.
    SEMINARS IN HEMATOLOGY, 2012, 49 (04) : 312 - 322
  • [5] EFFECT OF LENALIDOMIDE EXPOSURE ON RESPONSE AND OUTCOMES IN PATIENTS WITH LOWER-RISK NON-DEL(5Q) MYELODYSPLASTIC SYNDROMES (MDS)
    Garcia-Manero, G.
    Santini, V.
    Almeida, A.
    Fenaux, P.
    Gattermann, N.
    Ozawa, K.
    Goldberg, S. L.
    Weaver, J.
    Sugrue, M. M.
    LEUKEMIA RESEARCH, 2017, 55 : S51 - S51
  • [6] Effect of Lenalidomide (LEN) Exposure on Response and Outcomes in Patients (Pts) with Lower-Risk Non-Del(5q) Myelodysplastic Syndromes (MDS)
    Garcia-Manero, Guillermo
    Santini, Valeria
    Almeida, Antonio
    Fenaux, Pierre
    Gatterman, Norbert
    Ozawa, Keiya
    Goldberg, Stuart L.
    Weaver, Jerry
    Sugrue, Mary M.
    BLOOD, 2016, 128 (22)
  • [7] Recent advances in the treatment of lower-risk non-del(5q) myelodysplastic syndromes (MDS)
    Almeida, Antonio
    Fenaux, Pierre
    List, Alan F.
    Raza, Azra
    Platzbecker, Uwe
    Santini, Valeria
    LEUKEMIA RESEARCH, 2017, 52 : 50 - 57
  • [8] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Sekeres, Mikkael A.
    Swern, Arlene S.
    Giagounidis, Aristoteles
    List, Alan F.
    Selleslag, Dominik
    Mittelman, Moshe
    Schlegelberger, Brigitte
    Goehring, Gudrun
    Li, Jack Shiansong
    Sugrue, Mary M.
    Fenaux, Pierre
    BLOOD CANCER JOURNAL, 2018, 8
  • [9] The impact of lenalidomide exposure on response and outcomes in patients with lower-risk myelodysplastic syndromes and del(5q)
    Mikkael A. Sekeres
    Arlene S. Swern
    Aristoteles Giagounidis
    Alan F. List
    Dominik Selleslag
    Moshe Mittelman
    Brigitte Schlegelberger
    Gudrun Göhring
    Jack Shiansong Li
    Mary M. Sugrue
    Pierre Fenaux
    Blood Cancer Journal, 8
  • [10] Identification of Lenalidomide Sensitivity and Resistance Mechanisms in Non-Del(5q) Myelodysplastic Syndromes
    Drusbosky, Leylah M.
    Cogle, Christopher R.
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2020, 21 (09)
12345